Medicinal composite for treating Alzheimer's disease

Abstract

The invention discloses a medicinal composite for treating Alzheimer's disease. The medicinal composite for treating the Alzheimer's disease comprises procyanidine and cysteine, wherein the mass ratio of the procyanidine to the cysteine is (0.1-10):1, preferably (1-3):1; and the procyanidine is preferably lotus procyanidine. The medicinal composite for treating the Alzheimer's disease can improve the oxidation resistance of brain tissue, avoid free radical injury to the brain tissue, inhibit MAO-B and AchE activity and enhance the oxidation resistance of brain and hippocampal anti-oxidation system and serum so as to improve the learning and memory function. According to animal tests, the medicinal composite for treating the Alzheimer's disease can effectively improve mouse learning and memory injury induced by ethanol and scopolamine, and the curative effect is more excellent than that of piracetam and procyanidine.

Description

Technical field [0001] The present invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating Alzheimer's disease. Background technique [0002] With the rapid development of population aging, Alzheimer's disease has become the fourth leading cause of life-threatening diseases in the elderly. Alzheimer's disease (AD), also known as senile dementia, is a degenerative disease of the central nervous system with an insidious onset and a chronic and progressive course. It is the most common type of senile dementia. Mainly manifested as neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality change and language impairment, which seriously affect social, professional and life functions. The etiology and pathogenesis of AD have not yet been elucidated. The characteristic pathological changes are extracellular senile plaques formed by β-amyloid deposition, intra-nerve neurofibrillary tangles...

AI Technical Summary

Problems solved by technology

In addition, more and more epidemiological studies have shown that nutritional deficiency is closely related to the occurrence of AD, and AD patients lack certain nutrients, which suggests that increasing the intake of some special nutrients in AD patients may have Slow the progression of AD

So far, there have been no reports about the application of proanthocyanidins and cysteine ​​compositions in anti-Alzheimer's disease drugs at home and abroad

Images